The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval for AVT03, Alvotech's proposed biosimilar to Prolia and Xgeva. This positive opinion marks a significant regulatory milestone for the Icelandic biotech company, bringing the medication one step closer to European market availability. The recommendation covers both the 60 mg/mL pre-filled syringe formulation and the 70 mg/mL vial version of the denosumab biosimilar.

AVT03 functions as a human monoclonal antibody that targets the RANK ligand membrane protein, reducing osteoclast activity to decrease bone resorption. Prolia is indicated for treating osteoporosis in postmenopausal women and men at increased fracture risk, while Xgeva prevents bone complications in adults with advanced cancer that has spread to bone. The biosimilar approach aims to provide comparable therapeutic benefits while potentially increasing affordability and access.

Upon final approval by the European Commission, STADA Arzneimittel AG will market the biosimilar under the brand names Kefdensis for the 60 mg/mL formulation and Zvogra for the 70 mg/mL version. Dr. Reddy's Laboratories SA will offer corresponding products named Acvybra and Xbonzy. Both partners hold semi-exclusive commercial rights across Europe, including Switzerland and the United Kingdom.

Joseph McClellan, Alvotech's Chief Scientific and Technical Officer, stated that this development demonstrates how the company's specialized biosimilars platform enables broader access to affordable biologic medicines. The product remains under EMA regulatory review pending a final decision by the European Commission, which typically follows the CHMP's positive recommendation within several months.

Swedish prosecutors have charged four men aged 20 to 24 with robbery and assault in connection with three separate incidents that occurred in central Stockholm on August 27. The charges include allegations of unprovoked violent attacks with a hate crime motivation, according to court documents released by the Swedish Prosecution Authority.

The defendants are accused of robbing one individual and threatening that person's friend in Stockholm's city center, followed by what prosecutors describe as a severe assault against another person later the same night. Three of the men face additional charges for an assault that took place on the Stockholm metro system during the same evening. All victims in the three separate incidents were reported to have foreign backgrounds, though they had no connection to each other.

Prosecutor Gustav Andersson, who led the preliminary investigation, stated that surveillance footage and photographs show some of the defendants making Nazi salutes in connection with the alleged crimes. During house searches, authorities reportedly discovered materials and symbols indicating connections to right-wing extremism. The indictment specifically references the neo-Nazi and violence-promoting Aktivklubb movement as evidence of the motive behind the alleged offenses.

The Aktivklubb movement represents part of a larger international right-wing extremist network that outwardly focuses on strength training and martial arts. In Sweden, the movement gained traction in 2023 through the Aktivklubb Sverige network, which serves as an umbrella organization for local clubs. According to the Expo Foundation's 2024 annual report, five groups from Skåne to Hälsingland are part of Aktivklubb Sverige, with the number of registered activities increasing significantly last year.